Company

Metacrine, Inc.

Headquarters: San Diego, CA, United States

Employees: 35

CEO: Dr. Preston S. Klassen

NASDAQ: MTCR

Market Cap

$18.8 Million

USD as of Jan. 1, 2023

Market Cap History

Metacrine, Inc. market capitalization over time

Evolution of Metacrine, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Metacrine, Inc.

Detailed Description

Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with liver and gastrointestinal diseases. It is developing MET409 that has completed Phase 1b proof-of-concept clinical trial for the treatment of patients with non-alcoholic steatohepatitis (NASH); and is in Phase 2a clinical trial in combination with empagliflozin for the treatment of patients with type 2 diabetes mellitus and NASH. The company also develops MET642, which is in Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis patients. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

Metacrine, Inc. has the following listings and related stock indices.


Stock: NASDAQ: MTCR wb_incandescent

Details

Headquarters:

3985 Sorrento Valley Boulevard

Suite C

San Diego, CA 92121

United States

Phone: 858-369-7800

Fax: 858-369-7825